[{"edinetCode":"E24187","endDate":"2017\/5\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":726.0,"averageTemporaryStaff":32.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3448445.0,"sharesOwendPercent":0.2836,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":2027.0,"equityRatio":0.555,"cashAndCashEquivalents":1617337000.0,"assets":45707887000.0,"currentAssets":24345715000.0,"fixedAsset":21362172000.0,"tangibleFixedAssets":17878382000.0,"intangibleFixedAssets":321926000.0,"investmentAndOtherAssets":3161862000.0,"liabilities":19894005000.0,"currentLiabilities":15234979000.0,"shorTermDept":2750000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2054982000.0,"fixedLiabilities":4659026000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3694420000.0,"netAsset":25813882000.0,"capitalStock":24220112000.0,"capital":4367774000.0,"capitalSurplus":4253965000.0,"accumulatedEarnings":15610119000.0,"treasuryStock":-11746000.0,"valuationAndConversionAdjustments":1146029000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":37984428000.0,"costOfSales":30232301000.0,"grossProfit":7752127000.0,"sgaExpenses":3908893000.0,"salaryAndBenefit":579958000.0,"depreciationAndSGA":199850000.0,"RDExpenses":1266588000.0,"operatingIncome":3832165000.0,"nonOperatingIncome":169270000.0,"nonOperatingExpenses":122607000.0,"interestExpense":28565000.0,"ordinaryProfit":3878829000.0,"extraordinaryGain":292204000.0,"extraordinaryLoss":285830000.0,"incomeBeforeTax":3885202000.0,"incomeTaxes":1258186000.0,"netIncome":2627016000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2656281000.0,"comprehensiveIncome":2527301000.0,"eps":212.26,"dilutedEps":null,"dividendPerShare":null,"per":10.56,"roe":0.105,"cashFlowFromOperatingActivities":5069743000.0,"depreciationAndCashflowFromOperatingActivities":2818202000.0,"cashFlowFromInvestingActivities":-3011827000.0,"cashFlowFromFinancialActivities":-1777711000.0,"changesInCashAndCashEquivalents":266201000.0,"列1":"asr","submitDate":"2017\/8\/30","stockCode":4577,"accountingYear":"第75期（自　平成28年６月１日　至　平成29年５月31日）","accountingYearStart":"2016\/6\/1","accountingYearEnd":"2017\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2018\/5\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":734.0,"averageTemporaryStaff":33.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3814275.0,"sharesOwendPercent":0.3048,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":2242.34,"equityRatio":0.595,"cashAndCashEquivalents":1711449000.0,"assets":47196133000.0,"currentAssets":25056326000.0,"fixedAsset":22139806000.0,"tangibleFixedAssets":18654177000.0,"intangibleFixedAssets":329985000.0,"investmentAndOtherAssets":3155644000.0,"liabilities":18700578000.0,"currentLiabilities":13683536000.0,"shorTermDept":1400000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1965314000.0,"fixedLiabilities":5017041000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4018755000.0,"netAsset":28495554000.0,"capitalStock":26848056000.0,"capital":4367774000.0,"capitalSurplus":4253965000.0,"accumulatedEarnings":18239096000.0,"treasuryStock":-12779000.0,"valuationAndConversionAdjustments":1212248000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":39875983000.0,"costOfSales":31765385000.0,"grossProfit":8110597000.0,"sgaExpenses":3957083000.0,"salaryAndBenefit":591338000.0,"depreciationAndSGA":126145000.0,"RDExpenses":1522562000.0,"operatingIncome":4161156000.0,"nonOperatingIncome":125343000.0,"nonOperatingExpenses":42472000.0,"interestExpense":24079000.0,"ordinaryProfit":4244028000.0,"extraordinaryGain":29224000.0,"extraordinaryLoss":10187000.0,"incomeBeforeTax":4263065000.0,"incomeTaxes":1250615000.0,"netIncome":3012450000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3041941000.0,"comprehensiveIncome":3095669000.0,"eps":243.08,"dilutedEps":null,"dividendPerShare":null,"per":14.87,"roe":0.108,"cashFlowFromOperatingActivities":5465342000.0,"depreciationAndCashflowFromOperatingActivities":2853155000.0,"cashFlowFromInvestingActivities":-3833093000.0,"cashFlowFromFinancialActivities":-1543585000.0,"changesInCashAndCashEquivalents":94112000.0,"列1":"asr","submitDate":"2018\/8\/30","stockCode":4577,"accountingYear":"第76期（自　平成29年６月１日　至　平成30年５月31日）","accountingYearStart":"2017\/6\/1","accountingYearEnd":"2018\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2019\/2\/28","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.611,"cashAndCashEquivalents":null,"assets":49193901000.0,"currentAssets":26526792000.0,"fixedAsset":22667109000.0,"tangibleFixedAssets":19068913000.0,"intangibleFixedAssets":297357000.0,"investmentAndOtherAssets":3300839000.0,"liabilities":18709872000.0,"currentLiabilities":14824020000.0,"shorTermDept":2360000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1832650000.0,"fixedLiabilities":3885852000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3185861000.0,"netAsset":30484029000.0,"capitalStock":28947690000.0,"capital":4367774000.0,"capitalSurplus":4253965000.0,"accumulatedEarnings":20339061000.0,"treasuryStock":-13110000.0,"valuationAndConversionAdjustments":1131765000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":30401398000.0,"costOfSales":23746489000.0,"grossProfit":6654909000.0,"sgaExpenses":2990617000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3665617000.0,"nonOperatingIncome":111591000.0,"nonOperatingExpenses":24199000.0,"interestExpense":15688000.0,"ordinaryProfit":3753009000.0,"extraordinaryGain":194928000.0,"extraordinaryLoss":184092000.0,"incomeBeforeTax":3763845000.0,"incomeTaxes":1224776000.0,"netIncome":2539069000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2550460000.0,"comprehensiveIncome":2439301000.0,"eps":203.81,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/4\/12","stockCode":4577,"accountingYear":null,"accountingYearStart":"2018\/6\/1","accountingYearEnd":"2019\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2019\/5\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":735.0,"averageTemporaryStaff":36.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4153807.0,"sharesOwendPercent":0.3319,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":2472.66,"equityRatio":0.662,"cashAndCashEquivalents":1819437000.0,"assets":46749073000.0,"currentAssets":24360544000.0,"fixedAsset":22388529000.0,"tangibleFixedAssets":18732066000.0,"intangibleFixedAssets":306503000.0,"investmentAndOtherAssets":3349958000.0,"liabilities":15399704000.0,"currentLiabilities":11617837000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1851948000.0,"fixedLiabilities":3781866000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3093607000.0,"netAsset":31349369000.0,"capitalStock":29910146000.0,"capital":4367774000.0,"capitalSurplus":4253965000.0,"accumulatedEarnings":21301628000.0,"treasuryStock":-13222000.0,"valuationAndConversionAdjustments":1031896000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":41134770000.0,"costOfSales":32463335000.0,"grossProfit":8671434000.0,"sgaExpenses":4124401000.0,"salaryAndBenefit":597702000.0,"depreciationAndSGA":122893000.0,"RDExpenses":1608789000.0,"operatingIncome":4547317000.0,"nonOperatingIncome":126244000.0,"nonOperatingExpenses":31912000.0,"interestExpense":20895000.0,"ordinaryProfit":4641649000.0,"extraordinaryGain":217100000.0,"extraordinaryLoss":239935000.0,"incomeBeforeTax":4618814000.0,"incomeTaxes":1122365000.0,"netIncome":3496448000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3513028000.0,"comprehensiveIncome":3304753000.0,"eps":280.73,"dilutedEps":null,"dividendPerShare":null,"per":11.99,"roe":0.114,"cashFlowFromOperatingActivities":6888157000.0,"depreciationAndCashflowFromOperatingActivities":2852527000.0,"cashFlowFromInvestingActivities":-3867430000.0,"cashFlowFromFinancialActivities":-2898100000.0,"changesInCashAndCashEquivalents":107987000.0,"列1":"asr","submitDate":"2019\/8\/30","stockCode":4577,"accountingYear":"第77期（自　平成30年６月１日　至　令和元年５月31日）","accountingYearStart":"2018\/6\/1","accountingYearEnd":"2019\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2019\/8\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.653,"cashAndCashEquivalents":null,"assets":48412966000.0,"currentAssets":26615261000.0,"fixedAsset":21797705000.0,"tangibleFixedAssets":18300965000.0,"intangibleFixedAssets":292149000.0,"investmentAndOtherAssets":3204590000.0,"liabilities":16439787000.0,"currentLiabilities":13068230000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1795380000.0,"fixedLiabilities":3371556000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2678953000.0,"netAsset":31973179000.0,"capitalStock":30580166000.0,"capital":4367774000.0,"capitalSurplus":4253965000.0,"accumulatedEarnings":21971709000.0,"treasuryStock":-13283000.0,"valuationAndConversionAdjustments":1013372000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":11658182000.0,"costOfSales":9426570000.0,"grossProfit":2231612000.0,"sgaExpenses":875903000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1356657000.0,"nonOperatingIncome":46229000.0,"nonOperatingExpenses":10456000.0,"interestExpense":3757000.0,"ordinaryProfit":1392429000.0,"extraordinaryGain":1349000.0,"extraordinaryLoss":15153000.0,"incomeBeforeTax":1378626000.0,"incomeTaxes":466901000.0,"netIncome":911724000.0,"netIncomeAttributableToOwnersOfTheParentCompany":920354000.0,"comprehensiveIncome":874144000.0,"eps":73.55,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/10\/11","stockCode":4577,"accountingYear":null,"accountingYearStart":"2019\/6\/1","accountingYearEnd":"2020\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2019\/11\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4214007.0,"sharesOwendPercent":0.3329,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.666,"cashAndCashEquivalents":2679869000.0,"assets":49856631000.0,"currentAssets":27978340000.0,"fixedAsset":21878290000.0,"tangibleFixedAssets":18086691000.0,"intangibleFixedAssets":300344000.0,"investmentAndOtherAssets":3491255000.0,"liabilities":16285778000.0,"currentLiabilities":13325722000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1730478000.0,"fixedLiabilities":2960056000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2264299000.0,"netAsset":33570852000.0,"capitalStock":32066040000.0,"capital":4569497000.0,"capitalSurplus":4455687000.0,"accumulatedEarnings":23054198000.0,"treasuryStock":-13342000.0,"valuationAndConversionAdjustments":1137842000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":23253840000.0,"costOfSales":18497477000.0,"grossProfit":4756363000.0,"sgaExpenses":1928377000.0,"salaryAndBenefit":303389000.0,"depreciationAndSGA":null,"RDExpenses":607325000.0,"operatingIncome":2829808000.0,"nonOperatingIncome":62526000.0,"nonOperatingExpenses":16707000.0,"interestExpense":6776000.0,"ordinaryProfit":2875627000.0,"extraordinaryGain":112036000.0,"extraordinaryLoss":24370000.0,"incomeBeforeTax":2963293000.0,"incomeTaxes":974967000.0,"netIncome":1988325000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2002843000.0,"comprehensiveIncome":2061532000.0,"eps":159.48,"dilutedEps":158.58,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2570829000.0,"depreciationAndCashflowFromOperatingActivities":1416511000.0,"cashFlowFromInvestingActivities":-908235000.0,"cashFlowFromFinancialActivities":-791849000.0,"changesInCashAndCashEquivalents":860432000.0,"列1":"q2r","submitDate":"2020\/1\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2019\/6\/1","accountingYearEnd":"2020\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2020\/2\/29","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.662,"cashAndCashEquivalents":null,"assets":52271804000.0,"currentAssets":29985391000.0,"fixedAsset":22286413000.0,"tangibleFixedAssets":18807261000.0,"intangibleFixedAssets":297149000.0,"investmentAndOtherAssets":3182002000.0,"liabilities":17273274000.0,"currentLiabilities":14701033000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1638243000.0,"fixedLiabilities":2572240000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1875018000.0,"netAsset":34998530000.0,"capitalStock":33667067000.0,"capital":4877467000.0,"capitalSurplus":4763657000.0,"accumulatedEarnings":24039353000.0,"treasuryStock":-13411000.0,"valuationAndConversionAdjustments":955001000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":34372922000.0,"costOfSales":26828116000.0,"grossProfit":7544806000.0,"sgaExpenses":2962528000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":4584450000.0,"nonOperatingIncome":92909000.0,"nonOperatingExpenses":34872000.0,"interestExpense":9611000.0,"ordinaryProfit":4642487000.0,"extraordinaryGain":204362000.0,"extraordinaryLoss":71724000.0,"incomeBeforeTax":4775124000.0,"incomeTaxes":1550569000.0,"netIncome":3224555000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3241139000.0,"comprehensiveIncome":3127784000.0,"eps":256.48,"dilutedEps":254.98,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/4\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2019\/6\/1","accountingYearEnd":"2020\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2020\/5\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":784.0,"averageTemporaryStaff":45.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4421707.0,"sharesOwendPercent":0.3356,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":2772.3,"equityRatio":0.673,"cashAndCashEquivalents":3084107000.0,"assets":54249734000.0,"currentAssets":30855157000.0,"fixedAsset":23394577000.0,"tangibleFixedAssets":19399603000.0,"intangibleFixedAssets":299353000.0,"investmentAndOtherAssets":3695619000.0,"liabilities":17381372000.0,"currentLiabilities":15054346000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1512425000.0,"fixedLiabilities":2327026000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1581182000.0,"netAsset":36868361000.0,"capitalStock":35356070000.0,"capital":5370181000.0,"capitalSurplus":5256371000.0,"accumulatedEarnings":24742928000.0,"treasuryStock":-13411000.0,"valuationAndConversionAdjustments":1149580000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":44991400000.0,"costOfSales":35512638000.0,"grossProfit":9478762000.0,"sgaExpenses":4127157000.0,"salaryAndBenefit":604859000.0,"depreciationAndSGA":113940000.0,"RDExpenses":1400562000.0,"operatingIncome":5357313000.0,"nonOperatingIncome":130936000.0,"nonOperatingExpenses":25402000.0,"interestExpense":11882000.0,"ordinaryProfit":5462847000.0,"extraordinaryGain":304362000.0,"extraordinaryLoss":172058000.0,"incomeBeforeTax":5595151000.0,"incomeTaxes":1670410000.0,"netIncome":3924741000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3944714000.0,"comprehensiveIncome":4014219000.0,"eps":309.66,"dilutedEps":307.44,"dividendPerShare":null,"per":14.08,"roe":0.117,"cashFlowFromOperatingActivities":4306265000.0,"depreciationAndCashflowFromOperatingActivities":2950483000.0,"cashFlowFromInvestingActivities":-2681441000.0,"cashFlowFromFinancialActivities":-350462000.0,"changesInCashAndCashEquivalents":1264670000.0,"列1":"asr","submitDate":"2020\/8\/28","stockCode":4577,"accountingYear":"第78期（自　令和元年６月１日　至　令和２年５月31日）","accountingYearStart":"2019\/6\/1","accountingYearEnd":"2020\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2020\/8\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.715,"cashAndCashEquivalents":null,"assets":54564793000.0,"currentAssets":31175172000.0,"fixedAsset":23389620000.0,"tangibleFixedAssets":19666772000.0,"intangibleFixedAssets":289930000.0,"investmentAndOtherAssets":3432916000.0,"liabilities":15209057000.0,"currentLiabilities":13165101000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1387607000.0,"fixedLiabilities":2043956000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1291346000.0,"netAsset":39355735000.0,"capitalStock":37935465000.0,"capital":6170445000.0,"capitalSurplus":6056636000.0,"accumulatedEarnings":25721967000.0,"treasuryStock":-13584000.0,"valuationAndConversionAdjustments":1069638000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":13703504000.0,"costOfSales":10564485000.0,"grossProfit":3139019000.0,"sgaExpenses":1192104000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1947337000.0,"nonOperatingIncome":37672000.0,"nonOperatingExpenses":19811000.0,"interestExpense":1976000.0,"ordinaryProfit":1965198000.0,"extraordinaryGain":null,"extraordinaryLoss":5547000.0,"incomeBeforeTax":1959651000.0,"incomeTaxes":644257000.0,"netIncome":1315393000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1321407000.0,"comprehensiveIncome":1232530000.0,"eps":98.08,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/10\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2020\/6\/1","accountingYearEnd":"2021\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2020\/11\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4876637.0,"sharesOwendPercent":0.3556,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.706,"cashAndCashEquivalents":3189115000.0,"assets":57079422000.0,"currentAssets":32535990000.0,"fixedAsset":24543432000.0,"tangibleFixedAssets":20712174000.0,"intangibleFixedAssets":287250000.0,"investmentAndOtherAssets":3544007000.0,"liabilities":16418654000.0,"currentLiabilities":14634015000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1237830000.0,"fixedLiabilities":1784639000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1026469000.0,"netAsset":40660768000.0,"capitalStock":39239289000.0,"capital":6271234000.0,"capitalSurplus":6157425000.0,"accumulatedEarnings":26824213000.0,"treasuryStock":-13584000.0,"valuationAndConversionAdjustments":1067789000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":26035653000.0,"costOfSales":20191813000.0,"grossProfit":5843840000.0,"sgaExpenses":2332962000.0,"salaryAndBenefit":328680000.0,"depreciationAndSGA":null,"RDExpenses":911126000.0,"operatingIncome":3512131000.0,"nonOperatingIncome":64135000.0,"nonOperatingExpenses":20965000.0,"interestExpense":3820000.0,"ordinaryProfit":3555300000.0,"extraordinaryGain":null,"extraordinaryLoss":5547000.0,"incomeBeforeTax":3549753000.0,"incomeTaxes":1136587000.0,"netIncome":2413165000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2423653000.0,"comprehensiveIncome":2336402000.0,"eps":178.3,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":1719351000.0,"depreciationAndCashflowFromOperatingActivities":1420356000.0,"cashFlowFromInvestingActivities":-2238163000.0,"cashFlowFromFinancialActivities":625104000.0,"changesInCashAndCashEquivalents":105008000.0,"列1":"q2r","submitDate":"2021\/1\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2020\/6\/1","accountingYearEnd":"2021\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2021\/2\/28","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.695,"cashAndCashEquivalents":null,"assets":59307351000.0,"currentAssets":33967825000.0,"fixedAsset":25339525000.0,"tangibleFixedAssets":21650389000.0,"intangibleFixedAssets":280696000.0,"investmentAndOtherAssets":3408439000.0,"liabilities":17753543000.0,"currentLiabilities":14679143000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1467334000.0,"fixedLiabilities":3074399000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2303684000.0,"netAsset":41553807000.0,"capitalStock":40200031000.0,"capital":6271234000.0,"capitalSurplus":6157425000.0,"accumulatedEarnings":27785066000.0,"treasuryStock":-13694000.0,"valuationAndConversionAdjustments":998653000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":37835931000.0,"costOfSales":28973020000.0,"grossProfit":8862910000.0,"sgaExpenses":3528821000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":5336895000.0,"nonOperatingIncome":121516000.0,"nonOperatingExpenses":36361000.0,"interestExpense":6383000.0,"ordinaryProfit":5422050000.0,"extraordinaryGain":155000.0,"extraordinaryLoss":5792000.0,"incomeBeforeTax":5416413000.0,"incomeTaxes":1733334000.0,"netIncome":3683079000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3699918000.0,"comprehensiveIncome":3544965000.0,"eps":271.39,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/4\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2020\/6\/1","accountingYearEnd":"2021\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2021\/5\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":846.0,"averageTemporaryStaff":54.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":5068596.0,"sharesOwendPercent":0.3697,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":3034.88,"equityRatio":0.721,"cashAndCashEquivalents":3372906000.0,"assets":57739365000.0,"currentAssets":32429904000.0,"fixedAsset":25309461000.0,"tangibleFixedAssets":21372031000.0,"intangibleFixedAssets":332688000.0,"investmentAndOtherAssets":3604741000.0,"liabilities":15822003000.0,"currentLiabilities":12858792000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1362317000.0,"fixedLiabilities":2963211000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2018865000.0,"netAsset":41917362000.0,"capitalStock":40746572000.0,"capital":6271234000.0,"capitalSurplus":6157425000.0,"accumulatedEarnings":28331607000.0,"treasuryStock":-13694000.0,"valuationAndConversionAdjustments":872387000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":48714993000.0,"costOfSales":37917256000.0,"grossProfit":10797736000.0,"sgaExpenses":4883086000.0,"salaryAndBenefit":656205000.0,"depreciationAndSGA":132002000.0,"RDExpenses":2032657000.0,"operatingIncome":5908827000.0,"nonOperatingIncome":197912000.0,"nonOperatingExpenses":39143000.0,"interestExpense":7850000.0,"ordinaryProfit":6067595000.0,"extraordinaryGain":125179000.0,"extraordinaryLoss":318868000.0,"incomeBeforeTax":5873906000.0,"incomeTaxes":1716873000.0,"netIncome":4157033000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4246459000.0,"comprehensiveIncome":3908520000.0,"eps":311.02,"dilutedEps":null,"dividendPerShare":null,"per":10.55,"roe":0.109,"cashFlowFromOperatingActivities":5182527000.0,"depreciationAndCashflowFromOperatingActivities":3154329000.0,"cashFlowFromInvestingActivities":-6324278000.0,"cashFlowFromFinancialActivities":1424760000.0,"changesInCashAndCashEquivalents":288798000.0,"列1":"asr","submitDate":"2021\/8\/26","stockCode":4577,"accountingYear":"第79期（自　令和２年６月１日　至　令和３年５月31日）","accountingYearStart":"2020\/6\/1","accountingYearEnd":"2021\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2021\/8\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.733,"cashAndCashEquivalents":null,"assets":58729625000.0,"currentAssets":33860260000.0,"fixedAsset":24869365000.0,"tangibleFixedAssets":21231660000.0,"intangibleFixedAssets":323335000.0,"investmentAndOtherAssets":3314369000.0,"liabilities":15386881000.0,"currentLiabilities":12714829000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1247300000.0,"fixedLiabilities":2672052000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1744046000.0,"netAsset":43342744000.0,"capitalStock":42251800000.0,"capital":6271234000.0,"capitalSurplus":6157425000.0,"accumulatedEarnings":29836835000.0,"treasuryStock":-13694000.0,"valuationAndConversionAdjustments":795156000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":11746666000.0,"costOfSales":8470047000.0,"grossProfit":3276619000.0,"sgaExpenses":916243000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":2360375000.0,"nonOperatingIncome":73217000.0,"nonOperatingExpenses":13847000.0,"interestExpense":2336000.0,"ordinaryProfit":2419744000.0,"extraordinaryGain":246610000.0,"extraordinaryLoss":24308000.0,"incomeBeforeTax":2642046000.0,"incomeTaxes":824887000.0,"netIncome":1817159000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1825087000.0,"comprehensiveIncome":1745241000.0,"eps":133.09,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/10\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2021\/6\/1","accountingYearEnd":"2022\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0},{"edinetCode":"E24187","endDate":"2021\/11\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":6046335.0,"sharesOwendPercent":0.4374,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.726,"cashAndCashEquivalents":3820621000.0,"assets":60961679000.0,"currentAssets":35934160000.0,"fixedAsset":25027519000.0,"tangibleFixedAssets":21362881000.0,"intangibleFixedAssets":382382000.0,"investmentAndOtherAssets":3282255000.0,"liabilities":16315604000.0,"currentLiabilities":13907600000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1128929000.0,"fixedLiabilities":2408004000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1497540000.0,"netAsset":44646075000.0,"capitalStock":43518136000.0,"capital":6426270000.0,"capitalSurplus":6312460000.0,"accumulatedEarnings":30793270000.0,"treasuryStock":-13864000.0,"valuationAndConversionAdjustments":759518000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":22463211000.0,"costOfSales":16404553000.0,"grossProfit":6058657000.0,"sgaExpenses":2181488000.0,"salaryAndBenefit":327671000.0,"depreciationAndSGA":null,"RDExpenses":673618000.0,"operatingIncome":3877169000.0,"nonOperatingIncome":119133000.0,"nonOperatingExpenses":14835000.0,"interestExpense":4099000.0,"ordinaryProfit":3981467000.0,"extraordinaryGain":246610000.0,"extraordinaryLoss":131818000.0,"incomeBeforeTax":4096259000.0,"incomeTaxes":1335985000.0,"netIncome":2760273000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2777074000.0,"comprehensiveIncome":2653571000.0,"eps":202.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2407574000.0,"depreciationAndCashflowFromOperatingActivities":1546034000.0,"cashFlowFromInvestingActivities":-1276059000.0,"cashFlowFromFinancialActivities":-680850000.0,"changesInCashAndCashEquivalents":447715000.0,"列1":"q2r","submitDate":"2022\/1\/14","stockCode":4577,"accountingYear":null,"accountingYearStart":"2021\/6\/1","accountingYearEnd":"2022\/5\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E24187","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2393,"settlementDate":"2022\/5\/31","submitterName":"ダイト株式会社","submitterNameEnglish":"Daito Pharmaceutical Co.,Ltd.","submitterNameKana":"ダイトカブシキガイシャ","location":"富山市八日町３２６番地","industory":"医薬品","corporateNumber":4230000000000.0}]